top of page
  • Sevda Mirali

Comments Regarding Joint USPTO–FDA Collaboration Initiatives

On February 6, 2023, the Committee for Justice filed comments with the U.S. Patent and Trademark Office regarding collaboration with the Food and Drug Administration on drug patents. CFJ urges the USPTO to consider the considerable risks before “fixing” the current patent system by undermining the protection of pharmaceutical innovation

Our comments can be viewed below or as a PDF here



bottom of page